Blueprint Medicines Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Blueprint Medicines Corporation
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
Sponsors of several new medicines are set to learn if their products are on track for pan-EU approval. One product on the list is Pfizer/Lilly’s osteoarthritis drug, tanezumab, which recently ran into trouble in the US.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Hoyle Pharmaceuticals, Inc.
- ImmunoCo, Inc.